• 1
    Narisawa S, Hasegawa H, Watanabe K, Millán JL. Stage-specific expression of alkaline phosphatase during neural development in the mouse. Dev Dyn. 1994; 201:22735.
  • 2
    Narisawa S, Fröhlander N, Millán JL. Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia. Dev Dyn. 1997; 208:43246.
  • 3
    Narisawa S, Wennberg S, Millán JL. Abnormal vitamin B6 metabolism in alkaline phosphatase knock-out mice causes multiple abnormalities, but not the impaired bone mineralization. J Pathol. 2001; 193:12533.
  • 4
    Fedde K, Blair L, Silverstein J, Coburn SP, Ryan LM, Weinstein RS, Waymire K, Narisawa S, Millán JL, MacGregor GR, Whyte MP. Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res. 1999; 14:201525.
  • 5
    Anderson HC, Sipe JB, Hessle L, Dhamyamraju R, Atti E, Camacho NP, Millán JL. Impaired calcification around matrix vesicles of growth plate and bone in alkaline phosphatase-deficient mice. Am J Pathol. 2004; 164:8417.
  • 6
    Millán JL. Mammalian alkaline phosphatases—from biology to applications in medicine and biotechnology. Weinheim, Germany: Wiley-Vch Verlag GmbH & Co. KGaA; 2006. p.6789.
  • 7
    Whyte MP. Physiological role of alkaline phosphatase explored in hypophosphatasia. Ann N Y Acad Sci. 2010; 1192:190200.
  • 8
    Hessle L, Johnson KA, Anderson HC, Narisawa S, Sali A, Goding JW, Terkeltaub R, Millán JL. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A. 2002; 99:94459.
  • 9
    Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millán JL. Concerted regulation of inorganic pyrophosphate and osteopontin by Akp2, Enpp1, and Ank—an integrated model of the pathogenesis of mineralization disorders. Am J Pathol. 2004; 164:1199209.
  • 10
    Waymire KG, Mahuren JD, Jaje JM, Guilarte TR, Coburn SP, MacGregor GR. Mice lacking tissue non-specific alkaline phosphatase die from seizures due to defective metabolism of vitamin B-6. Nat Genet. 1995; 11:4551.
  • 11
    Millán JL, Narisawa S, Lemire I, Thomas P, Loisel TP, Boileau G, Leonard P, Gramatikova S, Terkeltaub R, Camacho NP, McKee MD, Crine P, Whyte MP. Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res. 2008; 23:77787.
  • 12
    McKee MD, Nakano Y, Masica DL, Gray JJ, Lemire I, Heft R, Whyte MP, Crine P, Millán JL. Enzyme replacement therapy prevents dental defects in a model of hypophosphatasia. J Dent Res. 2011; 90:4706.
  • 13
    Yadav MC, Lemire I, Leonard P, Boileau G, Blond L, Beliveau M, Cory E, Sah RL, Whyte MP, Crine P, Millán JL. Dose response of bone-targeted enzyme replacement for murine hypophosphatasia. Bone. 2011; 49:2506.
  • 14
    Yadav MC, Cardoso de Oliveira R, Foster BL, Fong H, Cory E, Narisawa S, Sah RL, Somerman M, Whyte MP, Millán JL. Enzyme replacement prevents enamel defects in hypophosphatasia mice. J Bone Miner Res. 2012; 27:172234.
  • 15
    Wennberg C, Hessle L, Lundberg P, Mauro S, Narisawa S, Lerner UH, Millán JL. Functional characterization of osteoblasts and osteoclasts from alkaline phosphatase knockout mice. J Bone Miner Res. 2000; 15:187988.
  • 16
    Johnson K, Goding J, Van Etten D, Sali A, Hu SI, Farley D, Krug H, Hessle L, Millán JL, Terkeltaub R. Linked deficiencies in extracellular PPi and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res. 2003; 18:9941004.
  • 17
    Harmey D, Johnson KA, Zelken J, Camacho NP, Hoylaerts MF, Noda M, Terkeltaub R, Millán JL. Elevated skeletal osteopontin levels contribute to the hypophosphatasia phenotype in Akp2−/− mice. J Bone Miner Res. 2006; 21:137786.
  • 18
    Butler WT. The nature and significance of osteopontin. Connect Tissue Res. 1989; 23:12336.
  • 19
    Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H. Regulation of vascular calcification—roles of phosphate and osteopontin. Circ Res. 2005; 96:71722.
  • 20
    Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis-promoting protein osteopontin in the tumor microenvironment. J Cell Mol Med. 2010; 14:203744.
  • 21
    Goldberg HA, Warner KJ, Li MC, Hunter G. Binding of bone sialoprotein, osteopontin and synthetic polypeptides to hydroxyapatite. Connect Tissue Res. 2001; 42:2537.
  • 22
    Kazanecki CC, Uzwiak DJ, David T, Denhardt DT. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem. 2007; 102:91224.
  • 23
    Christensen B, Nielsen MS, Hsaelmann KF, Petersen TE, Sorensen ES. Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J. 2005; 390:28592.
  • 24
    Hunter GK, Kyle CL, Goldberg HA. Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J. 1994; 300:7238.
  • 25
    Jono S, Peinado C, Giachelli CM. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem. 2000; 275:20197203.
  • 26
    Pampena DA, Robertson KA, Litvinova O, Lajoie G, Goldberg HA, Hunter GK. Inhibition of hydroxyapatite formation by osteopontin phosphopeptides. Biochem J. 2004; 378:10837.
  • 27
    Addison WN, Masica DL, Gray JJ, McKee MD. Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J Bone Miner Res. 2010; 25:695705.
  • 28
    Stein GS, Lian JB, Stein JL, van Wijnen AJ, Frenkel B, Montecino M. Mechanisms regulating osteoblast proliferation and differentiation. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. San Diego: Academic Press; 1996. p.6986.
  • 29
    Beck GR, Zerler B, Moran M. Phosphate is a specific signal for induction of osteopontin gene expression. Proc Natl Acad Sci U S A. 2000; 97:83527.
  • 30
    Rittling SR, Denhardt DT. Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol. 1999; 7:10313.
  • 31
    Yoshitake H, Rittling SR, Denhardt DT. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci U S A. 1999; 96:815660.
  • 32
    Murshed M, Harmey D, Millán JL, McKee MD, Karsenty G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev. 2005; 19:1093104.
  • 33
    Kawamoto T. Use of a new adhesive film for the preparation of multi-purpose fresh-frozen sections from hard tissues, whole-animals, insects and plants. Arch Histol Cytol. 2003; 66:12343.
  • 34
    Prince CW, Oosawa T, Butler WT, Tomana M, Bhown AS, Bhown M, Schrohenloher RE. Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. J Biol Chem. 1987; 262:29007.
  • 35
    Kinoshita E, Kinoshita-Kikuta E, Koike T. Separation and detection of large phosphoproteins using Phos-tag SDS-PAGE. Nat Protoc. 2009; 4:151321.
  • 36
    Stec DE, Morimoto S, Sigmund CD. Vectors for high-level expression of cDNAs controlled by tissue-specific promoters in transgenic mice. Biotechniques. 2001; 31:25660.
  • 37
    Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in a symptomatic patients. N Engl J Med. 2000; 342:126671.
  • 38
    Hoshi K, Amizuka N, Oda K, Ikehara Y, Ozawa H. Immunolocalization of tissue non-specific alkaline phosphatase in mice. Histochem Cell Biol. 1997; 107:18391.
  • 39
    Linder CH, Englund UH, Narisawa S, Millán JL, Magnusson P. Isozyme profile and tissue-origin of alkaline phosphatases in mouse serum. Bone. 2013; 53(2):399408.
  • 40
    Chung CH, Golub EE, Forbes E, Tokuoka T, Shapiro IM. Mechanism of action of β-glycerophosphate on bone cell mineralization. Calcif Tissue Int. 1992; 51:30511.
  • 41
    Narisawa S, Harmey D, Yadav MC, O'Neill WC, Hoylaerts MF, Millán JL. Novel Inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification. J Bone Miner Res. 2007; 22:170010.
  • 42
    Fedde KN, Ambroziak B, LaBanca C, Henthorn PS, Whyte MP. Alkaline phosphatase modulates phosphorylation of three extracellular proteins: a hypophosphatasia fibroblast study. J Bone Miner Res. 1994; 9:A172.
  • 43
    Ciancaglini P, Yadav MC, Simao AMS, Narisawa S, Pizauro JM, Farquharson C, Hoylaerts MF, Millán JL. Kinetic analysis of substrate utilization by native and TNAP-, NPP1-, or PHOSPHO1-deficient matrix vesicles. J Bone Miner Res. 2010; 25:71623.
  • 44
    Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH, Wenkert D, Van Sickle BJ, Simmons JH, Edgar TS, Bauer ML, Hamdan MA, Bishop N, Lutz RE, McGinn M, Craig S, Moore JN, Taylor JW, Cleveland RH, Cranley WR, Lim R, Thacher TD, Mayhew JE, Downs M, Millán JL, Skrinar A, Crine P, Landy H. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012; 366:90613.
  • 45
    Yadav MC, Simao AMS, Narisawa S, Huesa C, McKee MD, Farquharson C, Millán JL. Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: a unified model of the mechanisms of initiation of skeletal calcification. J Bone Miner Res. 2011; 26:28697.
  • 46
    Whyte MP, Valdes R Jr, Ryan LM. Infantile hypophosphatasia: enzyme replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget bone disease. J Pediatr. 1982; 101:37986.
  • 47
    Whyte MP, McAlister WH, Patton LS, Magill L, Fallon MD, Lorentz WB, Herrod HG. Enzyme replacement therapy for infantile hypophosphatasia attempted by intravenous infusions of alkaline phosphatase-rich Paget plasma: results in three additional patients. J Pediatr. 1984; 105:92633.
  • 48
    Weninger M, Stinson RA, Plenk H Jr, Böck P, Pollak A. Biochemical and morphological effects of human hepatic alkaline phosphatase in a neonate with hypophosphatasia. Acta Paediatr Scand Suppl. 1989; 360:15460.
  • 49
    Whyte MP, Habib D, Coburn SP, Tecklenburg F, L. Ryan L, Fedde KN, Stinson RA. Failure of hyperphosphatasemia by intravenous infusion of purified placental alkaline phosphatase to correct severe hypophosphatasia: evidence against a role for circulating ALP in skeletal mineralization. J Bone Miner Res. 1992; 7(Suppl):S155.